Clinical trial · Observational
Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy
NCT03042442CI-TRIAL-00037669CDNPANcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the interrelationship between cachexia, neural invasion and diabetes in patients with pancreatic cancer. Thus the investigators propose to identify the protein expression levels of Activin and Midkine in plasma of patients with different stages of pancreatic adenocarcinoma compared with healthy patients and to evaluate the possible correlation with diabetes, tumor size and tumor stage.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Diabetes Mellitus | — | UNRESOLVED | — |
| Pain | — | UNRESOLVED | — |
| Pancreatic Cancer, Adult | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical, venous blood samples, pancreatic tissue | Other | — | UNRESOLVED |
| Follow-up | Other | — | UNRESOLVED |
| Point-of care biomarkers | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with pancreatic cancer
- description
- Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
- interventionNames
- Diagnostic Test: Point-of care biomarkers
- Other: Clinical, venous blood samples, pancreatic tissue
- Other: Follow-up
- label
- health patients (controls)
- description
- Health patients
- interventionNames
- Diagnostic Test: Point-of care biomarkers
- Other: Clinical, venous blood samples, pancreatic tissue
- Other: Follow-up
Primary outcomes (1)
- measure
- Rate of patients with loss of > 5% body weight
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age over 18 years old 2. EUS or surgery biopsy confirming the diagnosis of adenocarcinoma 3. Informed consent Exclusion Criteria: 1. obvious malabsorption 2. artificial nutrition 3. hyperthyroidism 4. major depression 5. other causes of malnutrition 6. refusing to enter the study
References
Publications (0)
Data not yet available
No reference posted for this study.